Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure

authors:

avatar Roya Atabakhshian 1 , avatar Faranak Kazerouni 1 , * , avatar Fariba Raygan 2 , avatar Hushang Amirrasouli 1 , avatar Ali Rahimipour 1 , avatar Nezhat Shakeri 3

Department of Laboratory Medicine, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Heart Department, Shahid Beheshti Hospital, Shahid Beheshti University of Medical Sciences, Kashan, Iran
Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
International Cardiovascular Research Journal: Vol.8, issue 4; e11675
published online: December 01, 2014
article type: Research Article
received: April 19, 2017
accepted: May 14, 2014

how to cite: Atabakhshian R , Kazerouni F, Raygan F , Amirrasouli H , Rahimipour A , et al. Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure. Int Cardiovasc Res J. 2014;8(4):e11675. 

Abstract

Background: Galectin-3 is a soluble ß-galactoside–binding lectin released by activated cardiac macrophages. Galectin-3 has been proposed for diagnosis and prognosis of HF patients.
Objectives: The present study aimed to investigate the relationship between galectin-3 as a biomarker and ejection fraction and functional capacity in the patients with compensated systolic heart failure.
Patients and Methods: In this study, serum levels of Galectin-3 were measured in 76 patients with compensated heart failure with New York Heart Association class I–IV and left ventricular ejection fraction < 45%. Galectin-3 was measured by an ELISA kit. Besides, echocardiography was used to evaluate left ventricular ejection fraction. Additionally, functional capacity was determined based on the patients’ ability to perform a set of activities. After all, the data were analyzed used t-test, Kruskal-Wallis, one–way ANOVA, and chi-square test. P < 0.05 was considered as statistically significant.
Results: The patients’ age ranged from 45 to 75 years, with the mean age of 63.85 ± 9 years. In addition 57.9% of the patients were male. The results revealed no significant correlation between Galectin-3 and age, body mass index, and estimated glomerular filtration rate. Also, no significant correlation was observed between Galectin-3 levels and left ventricular ejection fraction (P = 0.166) and functional capacity (P = 0.420). Yet, a significant difference was found between males and females regarding the mean of Galectin-3 (P = 0.039).
Conclusions:: The study results suggested that Galectin-3 could not be used as a marker of disease progression in the patients under treatment, which could probably be the result of medication use in these patients.

Fulltext

The full text is available in PDF.

References

  • 1.

    The references are available in PDF.